{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:59:16Z","timestamp":1783047556304,"version":"3.54.6"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/cmr.0b013e32835ae915","type":"journal-article","created":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T09:28:50Z","timestamp":1351762130000},"page":"21-26","source":"Crossref","is-referenced-by-count":12,"title":["Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Ruta","family":"Zukauskaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon T.","family":"Asmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfred","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3171\/2011.3.JNS091107","article-title":"Surgical management of melanoma brain metastases in patients treated with immunotherapy.","volume":"115","author":"Lonser","year":"2011","journal-title":"J Neurosurg"},{"key":"R3-4-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"key":"R4-4-20210129","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cncr.22905","article-title":"Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.","volume":"110","author":"Majer","year":"2007","journal-title":"Cancer"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ctrv.2008.05.003","article-title":"A rational surgical approach to the treatment of distant melanoma metastases.","volume":"34","author":"Martinez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-1507","article-title":"Successful treatment of melanoma brain metastases with adoptive cell therapy.","volume":"16","author":"Hong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases.","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"issue":"Suppl 6","key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"vi14","DOI":"10.1093\/annonc\/mdp256","article-title":"Staging of cutaneous melanoma.","volume":"20","author":"Mohr","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"R10-4-20210129","first-page":"S22","article-title":"Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the european organization for research and treatment of cancer melanoma cooperative group.","volume":"3","author":"Keilholz","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1080\/02841860801918521","article-title":"A phase II study of thalidomide in patients with brain metastases from malignant melanoma.","volume":"47","author":"Vestermark","year":"2008","journal-title":"Acta Oncol"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cncr.21081","article-title":"Temozolomide plus thalidomide in patients with brain metastases from melanoma.","volume":"103","author":"Hwu","year":"2005","journal-title":"Cancer"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phases II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-4-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma.","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases.","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"R16-4-20210129","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"key":"R17-4-20210129","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cncr.25631","article-title":"Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.","volume":"117","author":"Eigentler","year":"2011","journal-title":"Cancer"},{"key":"R18-4-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejca.2005.10.008","article-title":"Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.","volume":"42","author":"Muller-Horvat","year":"2006","journal-title":"Eur J Cancer"},{"key":"R19-4-20210129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002371-200201000-00009","article-title":"Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.","volume":"25","author":"Guirguis","year":"2002","journal-title":"J Immunother"},{"key":"R20-4-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ejca.2006.11.014","article-title":"Prospective comparison of 18F-fluorodeoxyglucose positron emission tomographycomputed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.","volume":"43","author":"Pfannenberg","year":"2007","journal-title":"Eur J Cancer"},{"key":"R21-4-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of gamma knife surgery for melanoma brain metastases.","volume":"114","author":"Liew","year":"2010","journal-title":"J Neurosurg"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.soc.2010.09.005","article-title":"The role of radiation therapy in the management of cutaneous melanoma.","volume":"20","author":"Rao","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","article-title":"Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.","volume":"22","author":"Agarwala","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-4-20210129","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ctrv.2007.04.003","article-title":"Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.","volume":"33","author":"Petrella","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R27-4-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00001622-200403000-00014","article-title":"Management of brain metastases in patients with melanoma.","volume":"16","author":"Tarhini","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"R28-4-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"R31-4-20210129","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1200\/jco.2011.29.15_suppl.8581","article-title":"Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases abstract.","volume":"29","author":"Heller","year":"2011","journal-title":"J Clin Oncol"},{"key":"R32-4-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","article-title":"Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.","volume":"21","author":"Weber","year":"2011","journal-title":"Melanoma Res"},{"key":"R33-4-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R34-4-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-10-23","article-title":"Therapy for metastatic melanoma: the past, present, and future.","volume":"10","author":"Finn","year":"2012","journal-title":"BMC Med"},{"issue":"Suppl","key":"R35-4-20210129","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1200\/jco.2011.29.15_suppl.8548","article-title":"An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.","volume":"29","author":"Dummer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R36-4-20210129","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"Suppl","key":"R37-4-20210129","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/jco.2012.30.15_suppl.8501","article-title":"BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600Ek mutation-positive melanoma with brain metastases (mets) abstract.","volume":"30","author":"Kirkwood","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0b013e32835ae915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:24:10Z","timestamp":1621887850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201302000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32835ae915","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}